Very Low Debt / Strong Balance SheetNear-zero debt and growing equity provide durable financial flexibility, lowering solvency risk and enabling the company to fund R&D, inventory and working capital without urgent external financing. This supports resilience through biotech cycle swings and strategic optionality.

Profitability Inflection And Higher Gross MarginsA clear shift to positive net income and a sizable gross margin expansion indicate improving product mix or pricing power. If maintained, higher gross margins can absorb SG&A and R&D, creating a pathway to sustainable operating profitability over the medium term.

Recurring Consumables And Fee-for-service Revenue StreamsA business model with consumables and contract services creates recurring demand and customer stickiness, supporting predictable revenue per lab and higher lifetime customer value. This structural mix mitigates cyclicality versus one-off product sales.

Bears Say

Weak Cash Generation / Negative Free Cash FlowRecurring negative free cash flow and very small operating cash flow versus reported earnings suggest cash conversion issues. Persistent cash deficits constrain reinvestment, may force external financing, and raise questions about the durability of reported net income improvements.

Operating Profit Still NegativeDespite net income turning positive, continuing EBIT losses imply core operations don't yet generate sufficient profit to cover overhead. This reflects structural cost or scale issues and means earnings gains may be fragile without sustained margin or revenue improvements.

Uneven And Weak Revenue TrendMulti-year uneven revenue trends and a negative aggregate growth metric indicate demand volatility or execution gaps. Limited top-line consistency hampers predictable scaling, raises dependence on a few products/customers, and complicates planning for stable margin expansion.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥112.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥18.20B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is May 20, 2026 which is in 73 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on Feb 12, 2026. The company reported ¥0.29 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.29.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 94,802,895 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of ¥0.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.829%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.